etformin has been the first-line antidiabetic drug for more than 60 years because of its distinct glucose-lowering effect and safety profile. The mechanism by which metformin reduces glucose production has received considerable attention, yet controversy still exists. The prevailing view is that metformin acts directly on hepatocytes to decrease gluconeogenesis in part through modulation of mitochondrial complex I activity, AMPactivated protein kinase (AMPK) activation and AMP concentration [1] [2] [3] . Metformin was also shown to enhance hepatic cytosolic redox state by inhibiting glycerol-3-phosphate dehydrogenase activity to decrease gluconeogenesis 4, 5 . However, metformin is an orally administered drug that reaches high concentrations in the small intestine with much lower serum concentrations 6 ; thus, the possibility cannot be excluded that its metabolic benefits might be due in part to actions in the intestine. In the gut, metformin could act on the gut microbiota population. The gut microbiota influences development of metabolic diseases, including T2D and non-alcoholic fatty liver disease (NAFLD) 7, 8 , and metformin was recently shown to alter the gut microbiome of individuals with T2D 9,10 . Transfer of fecal samples from metformin-treated donors to germ-free mice phenocopied metformin treatment, and this effect was thought to be partially due to altered metal homeostasis 10 . Some studies also suggest that metformin treatment improves glucose homeostasis in obese mice and rats by modulating the gut microbiota [11] [12] [13] [14] . However, which species of the gut microbiota were affected by metformin and the underlying mechanism of how changes in the gut microbiota regulates host glucose metabolism is not clear.
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The gut microbiota influences host metabolism via the modulation of metabolites, including the endotoxin LPS, bile acids, trimethylamine N-oxide, and short chain fatty acids, in part by mediating the interaction between the gastrointestinal system and other organs 15 . The primary bile acids, cholic acid (CA) and chenodeoxycholic acid (CDCA) in humans and α /β -muricholic acid (α /β MCA) in mice, are synthesized from cholesterol in the liver and secreted as glycine and taurine conjugates into the intestine, respectively. In the gut, primary bile acids are transformed into secondary bile acids by the metabolic activities of enteric anaerobic bacteria 16 . Bile acids can alter metabolism by binding to nuclear receptors, including FXR (encoded by FXR, official symbol: NR1H4), pregnane X receptor and vitamin D receptor, as well as to the Takeda G-protein-coupled receptor 5 (TGR5) 16, 17 . Recent reports revealed that gut microbiota-mediated deconjugation of bile acids influences hepatic de novo bile acid synthesis, dependent on the FXRfibroblast growth factor (FGF)15 axis in mice [18] [19] [20] . FXR is a ligand-activated nuclear receptor that regulates hepatic bile acid biosynthesis, transport and secretion and is involved in 16 . Bile acids such as CA and CDCA are agonists of FXR, and activation of the FXR-small heterodimer partner (SHP, encoded by SHP, official symbol: NR0B2) axis in the liver inhibits the sterol 12 α -hydroxylase (CYP8B1) expression and bile acid synthesis 20 . In contrast, the conjugated bile acid, tauro-β -muricholic acid (Tβ MCA), is a natural FXR antagonist in mice [21] [22] [23] . Furthermore, inhibition of intestinal FXR prevented obesity-related metabolic dysfunction in mice [23] [24] [25] [26] . However, human and mouse bile acid profiles are known to differ, most notably due to the synthesis of MCA in mice and the predominance of taurine conjugation in mice and glycine conjugation in humans 23 . Because humans do not produce Tβ MCA, it remains unclear whether there is a natural bile acid that has FXR antagonist activity in humans.
The current study revealed that metformin treatment increased the levels of the bile acid glycoursodeoxycholic acid (GUDCA) in the gut by decreasing the abundance of species of B. fragilis and its bile salt hydrolase (BSH) activity in the intestines of individuals with T2D, as revealed by metagenomics sequencing analysis and metabolomics analysis. Furthermore, we identified GUDCA as a new endogenous antagonist of intestinal FXR. These results suggested that the metformin-induced improvement of metabolism is mediated by a B. fragilis-GUDCA-intestinal FXR axis in humans. Moreover, oral GUDCA supplementation or a synthetic FXR antagonist may be of potential translational value in the clinical treatment of T2D.
Results
Oral metformin modulates gut microbiota and bile acid metabolism in individuals with T2D. To investigate how oral metformin controls gut microbiota and metabolites in humans, we collected serum and stool samples from 22 individuals with T2D before and after being naively treated with 1,000 mg metformin twice daily (b.i.d) for 3 d. We performed whole-genome shotgun sequencing of stool samples, and association studies of metagenomics profiling and clinical indicators provided in-depth insight into the function of specific gut microbiota on host metabolism. Although whole-gene counts were not changed, the Shannon diversity index (α -diversity) of gut microbiota was slightly decreased after metformin treatment ( Supplementary Fig. 1a,b) . The plot from the partial least squares discriminant analysis (PLS-DA) showed that the gut microbiota composition was substantially reshaped after metformin treatment (Fig. 1a) . The variable importance in projection (VIP) score of the gut microbiota indicated that the species Bacteroides finegoldii and B. fragilis were the top gut microbiota that resulted in the group separation (Fig. 1b) . Metagenomic analysis further revealed that the genus Bacteroides showed the largest reduction in abundance ( Supplementary Fig. 1c ). Among the genus Bacteroides, the abundances of multiple species were reduced after metformin treatment, with the decrease in level of B. fragilis exhibiting the most striking change (Fig. 1c) . Clinical metformin treatment was found to be related to the modulation of bile acid profiles in individuals with T2D 10 . We adopted Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to suggest that Blautia obeum and B. fragilis were the top changed bacterial species on the pathway of secondary bile acid metabolism regulated by metformin ( Supplementary Fig. 1d ). We further used ultra-performance liquid chromatography-coupled time-of-flight mass spectrometry (UPLC-ESI-QTOFMS) metabolite profiling to quantitate bile acid levels in the serum and stool. The levels of GUDCA and tauroursodeoxycholic acid (TUDCA), conjugated secondary bile acids in humans, were predominantly elevated after metformin treatment ( Fig. 1d and Supplementary Fig. 1e ). Total bile acid levels remained unchanged, whereas noticeable elevation in ratios of conjugated to unconjugated bile acids was observed ( Supplementary Fig. 1f-i) . There was no difference in the ratio of 12α -OH to non-12α -OH bile acids ( Supplementary Fig. 1j,k) . These results suggest that oral metformin treatment regulates the gut microbiota and bile acid metabolism in individuals with T2D.
GUDCA is an FXR antagonist. Bile acids and their metabolites are important bioactive ligands that interact with receptors in the gut to regulate metabolic processes 19, 23 . In the distal ileum, FXR is activated by bile acids and induces expression of the FGF19 gene in humans (Fgf15 in mice). FGF19 levels in serum of individuals with T2D were dramatically decreased, and 7α -hydroxy-4-cholesten-3-one (C4) levels were markedly increased after metformin treatment, suggesting that intestinal FXR signaling was suppressed and hepatic CYP7A1 activity was increased after metformin treatment (Fig. 1e,f) .
Previously, in silico molecular docking studies of the FXR antagonist glycine-muricholic acid (GMCA) were carried out 25 . GMCA docked into the FXR ligand binding domain, establishing hydrogen bonds with some of the residues involved in noncovalent interactions with the FXR agonist CDCA 25 . GW4064, GMCA, TUDCA and GUDCA were docked into the human FXR ligand binding domain (PDB 3DCT, R4). GMCA, TUDCA and GUDCA docked with a much lower score of − 15.68 (GMCA), − 18.29 (TUDCA) and − 13.83 (GUDCA), and with a similar pose surrounded by residues Arg331, Met265, His447 and Tyr369 ( Supplementary Fig. 2a,b ). GW4064 docked with a score of − 55, reproducing the crystallographic binding pattern (PDB 3DCT, Supplementary Fig. 2c ) 27 . Similar to GW4064, TUDCA and GUDCA establish a salt bridge and a hydrogen bond interaction between the acidic groups and the side chain of Arg331 and backbone NH of Met265 ( Supplementary Fig. 2c-e) . Additionally, the 7β -OHs of TUDCA and GUDCA do not interact with the side chain of Tyr369.
To assess whether GUDCA and TUDCA were direct FXR antagonists, we applied the TR-FRET FXR coactivator assay. Neither GUDCA nor TUDCA showed agonistic action with CDCA as a positive control (EC 50 = 11.1 μ Μ , Supplementary Fig. 2f ). In the presence of CDCA, we found that GUDCA (IC 50 = 77.2 μ Μ ) and TUDCA (IC 50 = 75.1 μ Μ ) were FXR antagonists with comparable IC 50 s to that of Tβ MCA (IC 50 = 83.3 μ Μ , Fig. 2a and Supplementary  Fig. 2g,h ). Luciferase reporter gene assays revealed that both GUDCA and TUDCA markedly inhibited CDCA-induced FXR transcriptional activity (Fig. 2b) . In the human intestinal Caco-2 cell line, induction of the FXR target genes SHP and FGF19 mRNAs by CDCA were substantially suppressed by GUDCA and TUDCA (Fig. 2c) . Furthermore, luciferase reporter gene assays demonstrated that GUDCA had no effects on TGR5 activity ( Supplementary Fig. 2i ). To examine the inhibition of FXR signaling by GUDCA and TUDCA in vivo, antibiotic-treated, microbiota-depleted mice were given TCA (an FXR agonist) combined with CDCA, GUDCA and TUDCA by gavage. We found that CDCA further elevated TCAinduced intestinal FXR signaling, whereas GUDCA and TUDCA attenuated TCA-activated intestinal FXR signaling (Fig. 2d) . These results indicated that GUDCA and TUDCA are potential FXR antagonists in vitro and in vivo.
Metformin inhibits intestinal FXR signaling via the gut microbiota in an AMPK-independent manner. The clinical therapeutic dose of metformin is 1,000 mg b.i.d (~25 mg/kg/d), similar to 225 mg/kg/d in mice after allometric scaling. Mice were given 1.5 mg/ml metformin in water, which was equivalent to 200 mg/kg/d, the safe and efficacious dose of metformin. Similar to GUDCA in humans, Tβ MCA and TUDCA levels in the ileum were substantially higher in metformin-treated mice than in vehicle-treated mice, whereas GUDCA was undetectable in mice ( Supplementary Fig. 3a) . Expression of FXR target gene mRNAs were markedly suppressed in the ileum of metformin-treated mice but remained unchanged in the liver (Fig. 2e and Supplementary Fig. 3b ). Metformin treatment upregulated hepatic Cyp7a1 mRNA levels, resulting from downregulation of the intestinal FXR-FGF15 axis (Fig. 2f) . As intestinal AMPK is a proposed target of metformin, we administered metformin (in water) to mice and saw no evidence of AMPKα activation in the intestine, whereas when metformin was administered using gavage, we observed a transient activation, but only with a high dose ( Supplementary Fig. 3c,d ). To further determine whether intestinal AMPK was involved in inhibition of intestinal FXR by metformin treatment, we detected AMPKα 1 (encoded by Ampka1, official symbol: Prkaa1) and AMPKα 2 (encoded by Ampka2, official symbol: Prkaa2) levels in the intestine. As AMPKα 1 is the main form of intestinal AMPKα ( Supplementary Fig. 3e,f) , we adopted intestine-specific AMPKα 1 knockout (Ampka1 Fig. 3g ). We found that in this mouse strain, metformin still attenuated intestinal FXR signaling ( Fig. 2g and Supplementary Fig. 3h ). To investigate whether the gut microbiota was involved in inhibition of intestinal FXR signaling by metformin, antibiotic-treated, microbiota-depleted mice were fed a HFD and given drinking water containing metformin. Metformin treatment The BM (before the metformin treatment) group is shown in black, and the AM (after 3-d metformin treatment) group is shown in red. PC1 and PC2 account for 12% and 6%, respectively, of the total variance. PERMANOVA with the Bray-Curtis distance was used to assess the significant difference between the two groups, and the result showed significant separation of the BM and AM groups (P = 0.0001). n = 22 individuals/group. b, VIP scores of PLS-DA. VIP scores were used to rank the ability of different taxa to discriminate between BM and AM groups. A taxon with VIP score > 1 was considered important in the discrimination. n = 22 individuals/group. c, Different species abundance (percent reads) of Bacteriodes based on metagenomics data. n = 22 individuals/group. q value (FDR-adjusted P value), P value determined by two-tailed Wilcoxon matched-pairs signed rank test. d, Bile acid levels in the stool. n = 22 individuals/group. P value was determined by two-tailed Wilcoxon matched-pairs signed rank test. e,f, Serum FGF19 (e) and C4 (f) levels. n = 22 individuals/group. P value was determined by two-tailed Wilcoxon matched-pairs signed rank test. All the data are presented as the mean ± s.e.m.
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suppressed intestinal FXR activation, but a further inhibition of FXR signaling was not observed in the group treated with metformin plus antibiotics compared with the group treated with antibiotics only ( Fig. 2h and Supplementary Fig. 3i ). Similar to the intestinal FXR levels, levels of Tβ MCA and TUDCA were substantially higher after treatment with metformin or antibiotics, but there was no further upregulation in the group treated with metaformin plus antibiotics compared with the group treated with antibiotics only ( Supplementary Fig. 3j ). Furthermore, in antibiotics-treated, microbiota-depleted mice, metformin did not inhibit TCA-activated intestinal FXR signaling, indicating that the inhibition of intestinal FXR signaling by metformin was dependent on the microbiota (Fig. 2i) . These results revealed that inhibition of intestinal FXR signaling by metformin depends on gut microbiota but not intestinal AMPK.
B. fragilis is correlated with changes in bile acid metabolites and FXR signaling in metformin-treated individuals with T2D. To identify the bacterium responsible for GUDCA and TUDCA metabolism in individuals with T2D, we evaluated the correlation between changes in the gut microbiome and bile acids. GUDCA and TUDCA levels in stool and serum samples were only negatively correlated with the presence of species B. fragilis ( Fig. 3a and Supplementary  Fig 4a-e) . We further analyzed the correlation between changes in the gut microbiota and clinical biochemical indexes. The abundance of B. fragilis was positively correlated with serum FGF19 levels and was negatively correlated with serum C4 levels ( Fig. 3b and Supplementary Fig 4f,g ). Metformin was reported to influence the growth of bacteria in vitro 28 and regulate microbial folate and methionine metabolism 29 . Metformin directly inhibited the growth of B. fragilis in a dose-dependent manner (Fig. 3c) ; more interestingly, KEGG pathway analysis of metagenomic data showed that B. fragilis was the most top-changed bacterial species on the pathway of folate synthesis and one-carbon pool production affected by metformin ( Supplementary Fig. 4h ,i). Metabolomic analysis revealed that the level of 5-methyl-tetrahydrofolate (5-methyl-THF), a methyl donor for homocysteine methylation to methionine, in metformin-treated B. fragilis, was higher than that in vehicle-treated B. fragilis, and the content of methionine in B. fragilis was lower after metformin treatment (Fig. 3d ,e and Supplementary Fig. 4j ,k). Supplementation of methionine restored metformin inhibition of B. fragilis growth in culture (Fig. 3f) . BSH, which deconjugates conjugated bile acids, was purified and characterized from B. fragilis 30 . Indeed, B. fragilis mediated the deconjugation of GUDCA and TUDCA in vitro ( Supplementary Fig. 4l ,m). To clarify whether the accumulation of GUDCA and TUDCA was due to suppression of BSH activity by metformin, we performed further analysis of the metagenomic data. The B. fragilis Bsh gene copy number and BSH activity were dramatically reduced after metformin treatment (Fig. 3g,h ). Metformin substantially diminished deconjugation of GUDCA in vehicletreated B. fragilis, but not when treated with caffeic acid phenethyl ester (CAPE), a BSH inhibitor (Fig. 3i) . Furthermore, the dihydrofolate reductase inhibitor trimethoprim (TMP) was found to inhibit B. fragilis-mediated hydrolysis of GUDCA (Fig. 3j ). In the mice fed a HFD, supplementation with TMP mimicked metformin effects on bile acid metabolism and intestinal FXR signaling (Fig. 3k,l) . These results suggested that metformin upregulates GUDCA levels via downregulation of BSH activity in B. fragilis, mainly resulting from disruption of B. fragilis folate and methionine metabolism. Thus, the modulation of B. fragilis levels by metformin could result in a change of bile acid composition and FXR signaling in the gut.
B. fragilis administration abrogates improvement of glucose metabolism by metformin. To uncover the effects of metformintreated microbiota on host glucose metabolism, we transplanted stool obtained from four individuals with T2D before (trans-BM) and after (trans-AM) metformin treatment to antibiotic-treated, microbiota-depleted mice fed a HFD. After stool transplantation, the abundance of B. fragilis in the trans-AM mice was much lower than that in trans-BM mice ( Supplementary Fig. 5a ). We observed a slight body weight loss in the trans-AM mice compared with the trans-BM mice ( Supplementary Fig. 5b ). Glucose intolerance and insulin resistance were substantially improved in mice colonized with gut microbiota after metformin treatment ( Supplementary Fig. 5c-h ). Stool transplantation altered bile acid metabolism in mice, as the levels of intestinal Tβ MCA and TUDCA were higher, and intestinal FXR signaling was substantially suppressed in trans-AM mice compared with trans-BM mice ( Supplementary Fig. 5i-k) . These observations showed that the beneficial effects of metformin could be transmitted by stool transplantation.
We found that colonization of B. fragilis resulted in higher body weight gain, impaired glucose tolerance, and lower insulin sensitivity compared with control, heat-killed B. fragilis, on a HFD ( Supplementary Fig. 6a-g ). Tβ MCA and TUDCA levels in the ileum were substantially reduced, and intestinal FXR signaling was greatly activated after B. fragilis colonization ( Supplementary Fig. 6h-j) . It is well established that inhibition of intestinal FXR ameliorates obesityrelated metabolic diseases via white adipose tissue browning 25 . Expression of thermogenic gene mRNAs, including Ucp1, Elovl3, and Pgc1a (official symbol: Ppargc1a), was markedly downregulated in subcutaneous white adipose tissue (sWAT) but not in epididymal white adipose tissue (eWAT) or brown adipose tissue (BAT), after B. fragilis treatment ( Supplementary Fig. 6k-m) .
To further clarify whether B. fragilis participated in metformininduced improvements of metabolic diseases, we gave B. fragilis to metformin-treated mice on a HFD using gavage for 4 weeks. The reduced body weight gain caused by metformin treatment . e, Relative expression of intestinal Fxr mRNA and its target gene mRNAs in mice treated with metformin on a HFD for 1 week. n = 5 mice/group. P value was determined by two-tailed Student's t-test (Shp: t 8 = 2.779, Fgf15: t 8 = 3.383). f, The relative expression of Cyp7a1, Cyp7b1, Cyp8b1 and Cyp27a1 mRNAs in the livers of metformin-treated mice after 1-week HFD feeding. n = 5 mice/group. P value was determined by two-tailed Student's t-test (Cyp7a1: t 8 = 2.805). g, Relative abundance of intestinal Fxr mRNA and its target gene mRNAs in metformin-treated Ampka1 fl/fl and Ampka1 ∆IE mice on a HFD for 1 week. n = 5 mice/group. P value was determined by one-way ANOVA with Tukey's correction (Shp: F 3,16 = 8.046, Fgf15: F 3,16 = 11.83). h, Relative expression of intestinal Fxr mRNA and its target gene mRNAs in antibiotics-treated, microbiota-depleted mice treated with metformin on a HFD for 1 week. n = 5 mice/group. P value was determined by one-way ANOVA with Tukey's correction (Shp: F 3,16 = 6.859, Fgf15: F 3,16 = 8.782). i, In microbiota-depleted mice, metformin had no effect in inhibiting the activation of intestinal FXR on top of TCA. The relative expression of Fxr and its target genes in the ileum. n = 6 mice/group. All the data are presented as the mean ± s.e.m.
was eliminated after B. fragilis treatment (Supplementary Fig. 7a) . B. fragilis treatment impaired improvements in glucose tolerance and insulin sensitivity by metformin (Fig. 4a-f) . The enhanced energy expenditure by metformin was substantially diminished by B. fragilis treatment (Fig. 4g) ; however, food intake was not affected (Supplementary Fig. 7b) . B. fragilis administration markedly abrogated up-regulation of Tβ MCA and TUDCA levels and decrease of intestinal FXR signaling in metformin-treated mice (Fig. 4h,i and Supplementary Fig. 7c ). The enhanced levels of thermogenic gene mRNAs in sWAT of metformin-treated mice was blunted by B. fragilis (Fig. 4j) , but not in eWAT or BAT ( Supplementary Fig. 7d,e) . To further explore the vital role of B. fragilis BSH in metformin's action on glucose metabolism, mice fed a HFD were treated with metformin with or without CAPE upon B. fragilis colonization after microbiota elimination by antibiotics. Metformin substantially ameliorated B. fragilis colonization-induced metabolic dysfunction, although no further improvements were seen in mice treated with metformin plus CAPE compared with mice treated with CAPE 
Relative luciferase activity P < 0.0001 P < 0.0001 Fig. 8a-g ). Metformin-treated mice that were colonized with B. fragilis displayed a higher metabolic rate than control; however, CAPE-treated mice were unresponsive to metformin in this regard ( Supplementary Fig. 8h,i) . Metformin noticeably inhibited intestinal FXR signaling in mice that were colonized with B. fragilis, but the drug had no further effects in CAPE-treated mice ( Supplementary Fig. 8j,k) . These results revealed that reduction of B. fragilis abundance and its BSH activity contributes to the improvements of glucose intolerance by metformin.
Intestinal FXR is essential for metformin-induced metabolic improvements. To further address the role of intestinal FXR in the action of metformin and evaluate the long-term effects, we placed intestinal-specific Fxr knockout (Fxr ∆IE (Fig. 5a-g and Supplementary Fig. 9a,b) . Metformin substantially elevated energy expenditure in Fxr fl/fl mice, but had no further effects in Fxr ∆IE mice ( Fig. 5h and Supplementary Fig. 9c ). In sWAT, metformin markedly upregulated the expression levels of thermogenic genes in Fxr fl/fl mice; whereas Fxr ΔIE mice were unresponsive to metformin ( Fig. 5i and Supplementary Fig. 9d,e) . Immunohistochemical staining and Western blot analysis confirmed the elevated biogenesis of beige adipocytes and the expression level of UCP1 in metformin-treated Fxr fl/fl mice, but no further upregulation was noted in Fxr ∆IE mice (Fig. 5j,k) . These data revealed that metformin has potential longterm effects in improving metabolic diseases dependent on intestinal FXR signaling.
GUDCA has therapeutic effects on glucose intolerance and insulin resistance. Because GUDCA was identified as a novel FXR antagonist, we further investigated whether GUDCA produced metabolic benefits in vivo. Oral administration of GUDCA suppressed FXR signaling in the gut, but did not affect FXR signaling in the liver (Fig. 6a and Supplementary Fig. 10a,b) . Analysis of bile acid profiles revealed that GUDCA and TUDCA levels were markedly higher, whereas other bile acid metabolites were not changed (Fig. 6b) . GUDCA treatment substantially restored glucose intolerance and insulin resistance and attenuated body weight gain in Fxr fl/fl mice, but not in Fxr ∆IE mice on a HFD ( Supplementary Fig. 10c-i ). The metabolic rates were markedly enhanced in GUDCA-treated Fxr fl/fl mice; however, Fxr ∆IE mice were unresponsive to GUDCA treatment ( Supplementary Fig. 10j,k) . Mechanistically, GUDCA treatment significantly induced the expression of thermogenesis-related genes in Fxr fl/fl mice and had no further induction in Fxr ∆IE mice (Supplementary Fig. 10l ). These results demonstrated that GUDCA selectively antagonizes intestinal FXR signaling and thus ameliorates insulin resistance. Furthermore, GUDCA treatment had therapeutic effects in reversing metabolic disorders in established obese mice (Fig. 6c-i and Supplementary Fig. 11a-c) . The levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were lower after GUDCA supplementation, indicating that there was no liver injury ( Supplementary Fig. 11d,e) . These metabolic improvements were consistent with an elevated metabolic rate ( Fig. 6j and Supplementary Fig. 11f ). In addition, GUDCA substantially elevated active glucagon-like peptide 1 (GLP1) production, possibly contributing to the improvement of glucose homeostasis (Fig. 6k) .
Discussion
Although AMPK is believed to be one of the principal targets of metformin 1, 3 , some studies revealed that metformin effects may be independent of AMPK 2 , as verified in the present study. Notably, metformin still suppressed intestinal FXR signaling in Ampka1 ΔIE mice. In microbiota-depleted mice, metformin did not affect intestinal FXR signaling on either a HFD or after FXR agonist (TCA) treatment. These results revealed that metformin inhibits intestinal FXR signaling via modulation of the gut microbiota, and not through intestinal AMPK signaling. While there are several studies associating the gut microbiota with metformin treatment in mouse models or individuals with T2D, the major changes in the gut microbiota (especially at the species level) are not consistent [9] [10] [11] [12] [13] 31 . The gut microbiota varies widely among populations and life style and can influence the effectiveness of drugs 9, 32 . Thus, it is of great interest to find the important microbial-derived metabolites and determine their host targets rather than focusing only on changes in specific gut microbiota. The current study aimed to investigate the impact of the gut microbiota, bile acid metabolism and related host targets on the regulation of glucose metabolism in individuals with T2D and obese mice.
Although an elevation of Escherichia and a decrease of Intestinibacter were found in metformin-treated Danish and Swedish patients, there were slight or no changes in a Chinese cohort 9 , consistent with the present findings. A recent study of human stool samples collected after metformin treatment for 2, 4 and 6 months revealed that the abundance of genus Bacteroides was reduced after metformin treatment 10 . To exclude the possibility that the metabolic phenotype improvements after long-term metformin treatment modified the gut microbiota, we collected samples from individuals with T2D naively metformin treated for only 3 d. The results revealed that the consistent decrease of Bacteroides abundance was due to a direct effect of metformin treatment, and not derived from the subsequent metabolic improvements. Another report also demonstrated that there was a remarkable decrease of Bacteroides levels in Asian individuals with T2D after acarbose treatment 33 . Surprisingly, the improvement effects of acarbose were more remarkable in cluster B (rich in Bacteroides) than . n = 22 individuals/group. P value was determined by two-tailed Wilcoxon matched-pairs signed rank test. h, The hydrolysis efficiency of d5-GUDCA by stool samples from individuals with T2D before (BM) and after (AM) metformin treatment. n = 22 individuals/group. P value was determined by two-tailed Wilcoxon matched-pairs signed rank test. i, The hydrolysis efficiency of GUDCA mediated by vehicle-and metformin-treated B. fragilis with or without caffeic acid phenethyl ester (CAPE, BSH activity inhibitor) in culture. n = 5 replicates/treatment. P values were determined by one-way ANOVA with Tukey's correction (F 3,16 = 13). j, The hydrolysis efficiency of GUDCA mediated by B. fragilis with or without TMP in culture. n = 5 replicates/treatment. P value was determined by two-tailed Student's t-test (t 8 = 15.2). k,l, Bile acid levels (k) and the relative expression of Fxr and its target genes (l) in the ileum after 1 week of TMP treatment on a HFD. n = 6 mice/group. P values were determined by two-tailed Student' t-test (Tβ MCA: t 10 = 3, Shp: t 10 = 2.703, Fgf15: t 10 = 2.288). All data are presented as the mean ± s.e.m.
cluster P (rich in Prevotella), indicating that the decrease of Bacteroides abundance was beneficial in T2D treatment 33 . Among Bacteroides, we found that only the species B. fragilis was strongly correlated with GUDCA and TUDCA levels and intestinal FXR signaling. Furthermore, according to the KEGG pathway, B. fragilis showed the most striking change on the pathway of folate biosynthesis and one-carbon pool under metformin treatment. Folate provides one-carbon units for various biosynthetic processes, including methionine, purine and thymine, which are required for bacterial growth and survival 34 . The current study found that metformin inhibited the growth of B. fragilis through modification of folate and methionine metabolism. The exact mechanism by which metformin regulates folate and methionine metabolism of B. fragilis needs further investigation. We further found that B. fragilis colonization exacerbated Deconjugation of d5-GUDCA (%) P = 0.0025 ** * metabolic disorders induced by a HFD regimen. Consistent with this, B. fragilis decreased the levels of Tβ MCA and TUDCA, resulting in activated intestinal FXR signaling in mice. Moreover, improvements of glucose metabolism in metformin-treated mice were reversed by B. fragilis. Through the application of the BSH inhibitor CAPE, we further verified that the beneficial effects of metformin were dependent on inhibition of BSH activity in B. fragilis.
The gut microbiota is known to influence host intestinal homeostasis, in part via metabolic pathways such as the short chain fatty acid (SCFA) and bile acid metabolism. We found that the levels of GUDCA and TUDCA, which were identified in this study as novel endogenous FXR antagonists, were upregulated after metformin treatment in T2D individuals, but downregulated in B. fragilis-colonized mice. CDCA is converted to UDCA by gut microbial 7α /β -dehydrogenation and UDCA is then transported from the intestine to the liver in humans through the enterohepatic circulation. In liver, the majority of UDCA is conjugated with glycine and taurine to produce GUDCA and TUDCA, which are transported into the gut and then reabsorbed into the ileum epithelial cells 19 . In mice, CDCA is oxidized to β MCA by hepatic Cyp2c70 and conjugated with taurine to produce the mouse-specific Tβ MCA 35 , an intestinal FXR antagonist 21, 22 . The conjugated bile acids also go through deconjugation mediated by gut microbiota-produced BSH, and thus they are markedly elevated in germ-free and antibiotic-treated mice 21, 22 . In the current study, we observed that deconjugation of GUDCA and TUDCA in humans was suppressed due to the decrease of B. fragilis BSH. UDCA treatment was reported to have protective effects on hepatic metabolic diseases 36 , and oral administration of UDCA resulted in lower serum FGF19 levels, indicating that intestinal FXR signaling might be suppressed 37 . Because UDCA was found not to be a direct FXR antagonist 38 , the underlying mechanism remains unclear. Surprisingly, the present study revealed that GUDCA and TUDCA were bona fide FXR antagonists. Thus, the metabolic benefits of UDCA may in part be due to GUDCA. We confirmed that GUDCA supplementation suppressed intestinal FXR signaling and alleviated obesity-related metabolic diseases in vivo. In the current study, we found that oral GUDCA supplementation did not result in disorders in bile acid metabolism or liver injury, thus indicating the potential safety of this compound. The observation of similar metabolic effects of GUDCA in mice and humans suggest that the gut microbiota-intestinal FXR signaling pathway and associated mechanism as detailed in mouse studies 21, 23, 24 translates to humans and suggests that this pathway can be exploited for drug development.
FXR, a ligand-activated member of the nuclear receptor superfamily, is mainly expressed in the liver and ileum and plays a critical role in the development of metabolic diseases 16 . In contrast to the role of hepatic FXR in metabolism, inhibition of intestinal FXR signaling was demonstrated to improve metabolic diseases 21, [23] [24] [25] [39] [40] [41] . A recent study showed that metformin improved the SGLT1-dependent glucose-sensing glucoregulatory pathway by elevating the upper small intestinal levels of genus Lactobacillus in a HFD-treated rat model 14 . In agreement with this study, we also observed that the abundance of species Lactobacillus sanfranciscensis was increased in T2D individuals after a brief (3-day) clinical metformin treatment, and Sglt1 mRNA was elevated in the upper small intestine of HFD-treated mice after metformin treatment (L. Sun, Q. Wu, X. Wang, and C. Jiang, unpublished observations). Furthermore, the genus Lactobacillus was found to affect FXR signaling in the upper small intestine 42 . Inhibition of intestinal FXR could be a common pathway that connects gut microbiota remodeling with the anti-diabetic effects of metformin. The selective intestinal FXR antagonist GMCA had preventive and therapeutic effects on metabolic dysfunctions, thus indicating that this pathway can be pharmacologically targeted 25, 43 . The FXR and TGR5 dual agonist INT-767 was observed to stimulate GLP-1 secretion, which suggested that FXR and TGR5 may coordinately stimulate secretion of GLP-1 (ref. 44 ). Supporting this view, a recent study showed that the metabolic benefits of fexeramine, an intestine-specific FXR agonist, are in part through modulating the gut microbiota resulting in higher levels of the bile acid lithocholic (generated through bacterial 7β -dehydroxylation of UDCA) to activate TGR5/GLP-1 signaling 45 . Interestingly, FXR deficiency and FXR inhibition in intestinal L cells promoted GLP-1 production and secretion in a glycolysis-dependent manner 40 . The current study revealed that inhibition of intestinal FXR by GUDCA treatment substantially elevated serum active GLP1 levels. Additionally, previous results revealed that activation of intestinal FXR signaling enhanced the synthesis of ceramide in the gut and elevated serum ceramide levels; ceramide treatment was shown to suppress the expression of thermogenesis-related genes in beige adipocytes 25 . In the current study, sWAT thermogenesisrelated genes were elevated in metformin-treated Fxr fl/fl mice and Fxr ∆IE mice, but there was no further effect in metformin-treated Fxr ∆IE mice. Further studies are needed to explore the role of intestinal ceramides in the metabolic improvements by metformin.
The present study partially explains how metformin improves obesity-induced glucose intolerance and insulin resistance via an AMPK-independent mechanism (Supplementary Fig. 11g ). We conclude that metformin can act through the gut microbiota to improve metabolic dysfunction and does so by a B. fragilis-GUDCA-intestinal FXR axis. As the target of metformin in the gut, GUDCA signaling shows promise as a potential target for the treatment of metabolic disease in humans. 
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Experimental design 1. Sample size
Describe how sample size was determined. The exact sample sizes (n = 3-8) for each experimental group/condition are listed in figure legends. Sample size was estimated on the basis of sample availability and previous studies. The power analysis was performed using StatMate version 2.0 (GraphPad Software, San Diego, CA).
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Human subjects were collected under the shown criteria, listed in the Online Methods (Page 32). Six-to 8-week-old male mice were divided at random into experimental groups, with at least 4 mice per group, and the mice did not show differences before treatment (Page 38-40).
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators involved in this study were not completely blinded during data collection and/or analysis during the sample collection and analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
